🇺🇸 FDA
Patent

US 11999777

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

granted A61KA61K2039/507A61K2039/54

Quick answer

US patent 11999777 (Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
68
CPC classes
A61K, A61K2039/507, A61K2039/54, A61K31/706, A61K39/215